Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Alpharma appoints new chief scientific officer
In this new role, Mr Warner will advise and guide multiple late-stage development projects, interface with regulatory agencies in the US and abroad, ensure technology platforms provide distinct
In this new role, Mr Warner will advise and guide multiple late-stage development projects, interface with regulatory agencies in the US and abroad, ensure technology platforms provide distinct
Empirica Signal joins the Empirica Trace product as the newest component of Phase Forward’s Empirica suite of pharmacovigilance and risk management products, which are developed by the company’s
iCAD and American College of Radiology (ACR) Image Metrix, having completed the development portion of the study, are collaborating on study execution including a multi-reader, multi-case (MRMC) clinical
According to Cardium Therapeutics, the agreement covers InnerCool’s CoolBlue, a nurse-friendly and cost-effective surface cooling temperature modulation system, which was launched in the US market during the fourth
The products acquired from Vybion complement the growing portfolio of highly specialized biologicals that the company manufactures and distributes to the diagnostic, pharmaceutical and research markets, said Meridian.
The special protocol assessment (SPA) process allows for FDA evaluation of a clinical trial protocol intended to form the primary basis of an efficacy claim in support of
AeroLEF is being developed as a novel and effective approach to the management of acute pain by delivering a proprietary formulation of inhaled, nebulized, free-and-liposome-encapsulated fentanyl. The free
There are two pivotal studies running in parallel, one in North America and one in Europe. Each is a multicenter, randomized, double-blind, placebo-controlled efficacy study recruiting a total
This was achieved during the final comparative gene selection work carried out by Ark’s scientists in Finland in a second preclinical therapeutic proof-of-principle study. EG011, containing shortform vascular
Stem Cell Sciences (SCS) will incorporate the green fluorescent protein (GFP) technology, which acts as a gene expression marker, into its SC Proven research reagents portfolio as well